<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ovarian Res</journal-id><journal-id journal-id-type="iso-abbrev">J Ovarian Res</journal-id><journal-title-group><journal-title>Journal of Ovarian Research</journal-title></journal-title-group><issn pub-type="epub">1757-2215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7968266</article-id><article-id pub-id-type="publisher-id">794</article-id><article-id pub-id-type="doi">10.1186/s13048-021-00794-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Identification of potential markers for differentiating epithelial ovarian cancer from ovarian low malignant potential tumors through integrated bioinformatics analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hao</surname><given-names>Wende</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Hongyu</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhefeng</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Jiahao</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Meng</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhao</surname><given-names>Xiaoting</given-names></name><address><email>zhao_xiaoting@ccmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yue</surname><given-names>Wentao</given-names></name><address><email>yuewt@ccmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.24696.3f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0369 153X</institution-id><institution>Central Laboratory, Beijing Obstetrics and Gynecology Hospital, </institution><institution>Capital Medical University, </institution></institution-wrap>Beijing, 100026 China </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>14</volume><elocation-id>46</elocation-id><history><date date-type="received"><day>29</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>5</day><month>3</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Epithelial ovarian cancer (EOC), as a lethal malignancy in women, is often diagnosed as advanced stages. In contrast, intermediating between benign and malignant tumors, ovarian low malignant potential (LMP) tumors show a good prognosis. However, the differential diagnosis of the two diseases is not ideal, resulting in delays or unnecessary therapies. Therefore, unveiling the molecular differences between LMP and EOC may contribute to differential diagnosis and novel therapeutic and preventive policies development for EOC.</p></sec><sec><title>Methods</title><p id="Par2">In this study, three microarray data (GSE9899, GSE57477 and GSE27651) were used to explore the differentially expressed genes (DEGs) between LMP and EOC samples. Then, 5 genes were screened by protein&#x02013;protein interaction (PPI) network, receiver operating characteristic (ROC), survival and Pearson correlation analysis. Meanwhile, chemical-core gene network construction was performed to identify the potential drugs or risk factors for EOC based on 5 core genes. Finally, we also identified the potential function of the 5 genes for EOC through pathway analysis.</p></sec><sec><title>Results</title><p id="Par3">Two hundred thirty-four DEGs were successfully screened, including 81 up-regulated genes and 153 down-regulated genes. Then, 5 core genes (CCNB1, KIF20A, ASPM, AURKA, and KIF23) were identified through PPI network analysis, ROC analysis, survival and Pearson correlation analysis, which show better diagnostic efficiency and higher prognostic value for EOC. Furthermore, NetworkAnalyst was used to identify top 15 chemicals that link with the 5 core genes. Among them, 11 chemicals were potential drugs and 4 chemicals were risk factors for EOC. Finally, we found that all 5 core genes mainly regulate EOC development via the cell cycle pathway by the bioinformatic analysis.</p></sec><sec><title>Conclusion</title><p id="Par4">Based on an integrated bioinformatic analysis, we identified potential biomarkers, risk factors and drugs for EOC, which may help to provide new ideas for EOC diagnosis, condition appraisal, prevention and treatment in future.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13048-021-00794-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Epithelial ovarian cancer</kwd><kwd>Low malignant potential tumor</kwd><kwd>Integrated bioinformatical analysis</kwd><kwd>Chemicals</kwd><kwd>Diagnosis</kwd><kwd>Prognosis</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81672838 and 61431019</award-id><principal-award-recipient><name><surname>Yue</surname><given-names>Wentao</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Beijing Municipal Science &#x00026; Technology Commission </institution></funding-source><award-id>Z181100001718193</award-id><principal-award-recipient><name><surname>Yue</surname><given-names>Wentao</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par19">Epithelial ovarian cancer (EOC) has been reported to be the common cause of death for gynecological cancer [<xref ref-type="bibr" rid="CR1">1</xref>]. Moreover, most EOC cases were diagnosed as advanced due to their vague symptoms [<xref ref-type="bibr" rid="CR2">2</xref>]. Despite improvements in surgery and other treatments, the therapeutic efficacy and prognosis of EOC patients with advanced stage still remain worse due to lack of early and effective detection methods [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par20">Unlike EOC, LMP tumor is a unique epithelial subtype of ovarian tumor that intermediates between benign and malignant tumors [<xref ref-type="bibr" rid="CR4">4</xref>]. Meanwhile, LMP tumor is also known as borderline malignant ovarian cancer due to lack invasion of the underlying stroma [<xref ref-type="bibr" rid="CR5">5</xref>]. Thus, the prognosis of LMP and EOC differ considerably due to their different invasiveness, with 5-year survival rate&#x02009;&#x0003e;&#x02009;90% for LMP versus a&#x02009;&#x0003c;&#x02009;30% survival for advanced high-grade EOC [<xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore, unilateral oophorectomy should be considered in LMP patients in view of its younger onset age, which is different from EOC [<xref ref-type="bibr" rid="CR7">7</xref>]. However, a portion of LMP tumors display diffuse non-invasive extra-ovarian implants, and accurate identification of these implants can be very difficult [<xref ref-type="bibr" rid="CR4">4</xref>]. Moreover, approximately 20&#x02013;30% of LMP cases are finally confirmed to be EOC [<xref ref-type="bibr" rid="CR4">4</xref>]. Thus, it can be seen that the diagnosis based on histopathology without using molecular markers will lead to inaccurate diagnosis of LMP. Therefore, identifying potential differential diagnostic markers for LMP and EOC may improve the diagnostic accuracy and also contribute to the development of novel therapeutic &#x00026; preventive strategies for EOC.</p><p id="Par21">Recently, many integrated bioinformatical studies on EOC and normal samples have been shown to help explore the biomarkers and mechanisms of ovarian cancer occurrence and development [<xref ref-type="bibr" rid="CR8">8</xref>]. However, current integrated bioinformatical studies on LMP and EOC may be insufficient.</p><p id="Par22">In our study, DEGs between LMP and EOC were first screened based on three GEO datasets. Then, Kyoto Encyclopaedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses were performed for these DEGs. Next, PPI network, ROC, survival and Pearson correlation analysis were utilized to further validate core genes, which show better diagnostic efficiency and higher prognostic value for EOC. Furthermore, the chemical-core gene network was constructed based on 5 core genes, and the top 15 related chemicals for EOC were identified. Finally, we found that all 5 core genes mainly regulate EOC development via the cell cycle pathway by the bioinformatic analysis, which may help to provide new ideas for EOC treatment.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Data acquisition</title><p id="Par23">Four gene expression profiles (GSE9899, GSE27651, GSE12172, and GSE57477) were downloaded from the Gene expression omnibus (GEO) database (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo">http://www.ncbi.nlm.nih.gov/geo</ext-link>). GSE9899 included 18 ovarian LMP tumors and 267 EOC samples, GSE27651 included 8 LMP tumors and 22 EOC samples, GSE12172 comprised 30 LMP tumors and 60 EOC samples, and GSE57477 included 6 LMP tumors and 46 serous ovarian adenocarcinomas. The gene expression data of GSE9899, GSE27651 and GSE12172 were download from the platform of GPL570 (Affymetrix Human Genome U133 Plus 2.0 Array), whereas GSE57477&#x02019; gene expression data was download from the platform of GPL10558 (Illumina HumanHT-12&#x02009;V4.0 expression beadchip).</p></sec><sec id="Sec4"><title>DEGs identification</title><p id="Par24">The DEGs were identified between LMP tumors and EOC in GEO database by the Bioconductor package <italic>limma</italic> [<xref ref-type="bibr" rid="CR9">9</xref>]. We set the |log<sub>2</sub>FC|&#x02009;&#x0003e;&#x02009;1.0 and adjusted <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 for cutoff criteria. Then, the Venny online tool (<ext-link ext-link-type="uri" xlink:href="https://bioinfogp.cnb.csic.es/tools/venny/">https://bioinfogp.cnb.csic.es/tools/venny/</ext-link>) was applied to identify the overlapping DEGs among GSE9899, GSE57477 and GSE27651.</p></sec><sec id="Sec5"><title>Pathway analysis of DEGs</title><p id="Par25">GO and KEGG analysis of DEGs were performed through the DAVID (<ext-link ext-link-type="uri" xlink:href="https://david.ncifcrf.gov/">https://david.ncifcrf.gov/</ext-link>). The top 20 items of GO function pathways and all items of KEGG pathways were then displayed as bubble diagrams using the <italic>ggplot2</italic> R package based on <italic>P</italic>-value (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 as statistically significant).</p></sec><sec id="Sec6"><title>PPI and functional analysis</title><p id="Par26">STRING (<ext-link ext-link-type="uri" xlink:href="http://www.string-db.org/">http://www.string-db.org/</ext-link>) was utilized to build PPI network of the identified DEGs [<xref ref-type="bibr" rid="CR10">10</xref>]. Moreover, MCODE plugin from Cytoscape software (version 3.8.0) was performed to detect clusters of DEGs. Then, functional analysis of the genes in the hub module 1 were performed through the DAVID. Meanwhile, the top 20 hub genes were screened by the topological algorithm Maximal Clique Centrality (MCC) using the CytoHubba [<xref ref-type="bibr" rid="CR11">11</xref>].</p></sec><sec id="Sec7"><title>Genetic information of the top 20 potential hub genes</title><p id="Par27">The cBioPortal (<ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/">https://www.cbioportal.org/</ext-link>) was utilized to show the genetic information of the top 20 hub genes.</p></sec><sec id="Sec8"><title>Validation of hub genes</title><p id="Par28">The expression levels of the 20 genes between LMP tumors and EOC were verified through the GSE12172 dataset, and then the ROC and Kaplan&#x02013;Meier analysis were used to explore their differential diagnostic and prognosis value. <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significance.</p></sec><sec id="Sec9"><title>Pearson correlation analysis between 5 core genes&#x02019; expression and the level of different immune checkpoint proteins</title><p id="Par29">Through the ROC and survival analysis, we screened the top 5 core genes with better diagnostic efficiency and higher prognostic value for EOC. We further analyzed whether 5 core genes&#x02019; expression is related to the level of different immune checkpoint proteins through the Gene Expression Profiling Interactive Analysis (GEPIA) database (<ext-link ext-link-type="uri" xlink:href="http://gepia.cancer-pku.cn/detail.php">http://gepia.cancer-pku.cn/detail.php</ext-link>) [<xref ref-type="bibr" rid="CR12">12</xref>]. Then, the types of immune checkpoint proteins that are positively correlated with gene expression were selected and shown in picture.</p></sec><sec id="Sec10"><title>Chemical-core gene network analysis</title><p id="Par30">Then, the network of the 5 core genes and their related chemicals was analyzed through the open-source platform NetworkAnalyst (<ext-link ext-link-type="uri" xlink:href="https://www.networkanalyst.ca/">https://www.networkanalyst.ca/</ext-link>) [<xref ref-type="bibr" rid="CR13">13</xref>], and then visualized by Cytoscape software.</p></sec><sec id="Sec11"><title>KEGG and GO pathway analysis of the 5 core genes</title><p id="Par32">The genes that were co-expressed with 5 core genes in EOC patients in the TCGA database were identified through cBioportal (<ext-link ext-link-type="uri" xlink:href="http://cbioportal.org">http://cbioportal.org</ext-link>). Then, the co-expressed gene pairs with the Pearson correlation coefficient&#x02009;&#x02265;&#x02009;0.3 were selected for further KEGG analysis through the DAVID. The top ten enriched KEGG terms for each core gene were shown in the form of matrix bubble map based on -log10(<italic>P</italic> value) through the community-driven bioinformatics data visualization platform Hiplot (<ext-link ext-link-type="uri" xlink:href="https://hiplot.com.cn/basic/matrix-bubble">https://hiplot.com.cn/basic/matrix-bubble</ext-link>). Meanwhile, GO biological process analysis for 5 core genes were also performed by the application of ClueGO [<xref ref-type="bibr" rid="CR14">14</xref>] and CluePedia [<xref ref-type="bibr" rid="CR15">15</xref>]. kappa coefficient of 0.42 and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 were chosen as threshold values.</p></sec></sec><sec id="Sec12"><title>Results</title><sec id="Sec13"><title>DEGs identification</title><p id="Par33">Screening criteria on the basis of adjusted P&#x02009;&#x0003c;&#x02009;0.05 and |log<sub>2</sub>FC|&#x02009;&#x0003e;&#x02009;1.0, DEGs were screened between LMP and EOC samples in GSE27651, GSE57477, and GSE9899. Then, the DEGs were visualized as volcano plots (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a-c). Subsequently, 81 overlapping up-regulated genes and 153 down-regulated genes (Fig. <xref rid="Fig1" ref-type="fig">1</xref>d-e) were identified using Venny online tool.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Overlapping DEGs Identification. Volcano plots of DEGs in GSE27651 (<bold>a</bold>) GSE57477 (<bold>b</bold>) and GSE9899 (<bold>c</bold>), respectively. Venn plots of up-regulated (<bold>d</bold>) and down-regulated (<bold>e</bold>) overlapping DEGs among GSE27651, GSE57477, and GSE9899 datasets</p></caption><graphic xlink:href="13048_2021_794_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec14"><title>Pathway analysis</title><p id="Par34">For a further understanding of the three datasets&#x02019; overlapping DEGs, KEGG and GO analysis were carried out through DAVID. In KEGG analysis, the overlapping up-regulated genes were highly enriched in Cell cycle and Oocyte meiosis (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a), while the down-regulated genes were enriched in Huntington&#x02019;s disease (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). In GO analysis, the overlapping up-regulated genes were highly enriched in Protein binding, Nucleoplasm and Nucleus (Fig. <xref rid="Fig2" ref-type="fig">2</xref>c), and the down-regulated genes were mostly enriched in Cilium, Microtubule, and Motile cilium (Fig. <xref rid="Fig2" ref-type="fig">2</xref>d).
<fig id="Fig2"><label>Fig. 2</label><caption><p>KEGG and GO analysis of overlapping DEGs. <bold>a</bold> KEGG analysis of up-regulated genes. <bold>b</bold> KEGG analysis of down-regulated genes. <bold>c</bold> GO analysis of up-regulated genes. <bold>d</bold> GO analysis of down-regulated genes</p></caption><graphic xlink:href="13048_2021_794_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec15"><title>PPI network construction and cluster analysis</title><p id="Par35">The STRING database and the Cytoscape software were used to construct the PPI network of the overlapping DEGs in EOC. Finally, three important clusters were screened by MCODE. Among them, cluster 1 included 59 proteins with the highest score (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a), cluster 2 and 3 contained 15 and 5 proteins, respectively (Fig. <xref rid="Fig3" ref-type="fig">3</xref>b &#x00026; c). Additionally, we analyzed the function of cluster 1. In KEGG analysis, the cluster 1&#x02032; DEGs were mostly enriched in Cell cycle and Oocyte meiosis (Fig. <xref rid="Fig3" ref-type="fig">3</xref>d). In GO analysis, cluster 1&#x02032; DEGs were mostly enriched in Protein binding, Nucleoplasm and Nucleus (Fig. <xref rid="Fig3" ref-type="fig">3</xref>e).
<fig id="Fig3"><label>Fig. 3</label><caption><p>PPI network analysis. Cluster 1 (<bold>a</bold>), cluster 2 (<bold>b</bold>), cluster 3 (<bold>c</bold>). (note: red nodes represent up-regulated genes, while blue nodes represent down-regulated genes); <bold>d</bold> KEGG analysis of the genes in cluster 1. <bold>e</bold> GO analysis of the genes in cluster 1</p></caption><graphic xlink:href="13048_2021_794_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec16"><title>Hub gene identification and their genetic alteration information analysis</title><p id="Par36">We further used the cytoHubba to identify hub genes in PPI network according to the topological algorithm maximal clique centrality (MCC). To identify more interested genes, we selected the top 20 genes for further analysis, which were also included in cluster 1(Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a and Table S<xref rid="MOESM1" ref-type="media">1</xref>). Then, the genetic information of the 20 hub genes were shown through the cBioPortal (Fig. <xref rid="Fig4" ref-type="fig">4</xref>b &#x00026; c). These genes were altered in 154 (50%) EOC samples or patients. PBK (9%) and AURKA (9%) were altered most frequently. Meanwhile, amplification accounted for the highest percentage of these alterations.
<fig id="Fig4"><label>Fig. 4</label><caption><p>Hub genes and their genetic alterations identification. <bold>a</bold> The top 20 hub genes were identified through cytoHubba. (note: the redder the nodes color, the higher the ranking). <bold>b</bold> A visual summary of the hub genes&#x02019; genetic alterations in ovarian cancer samples. <bold>c</bold> An overview of the 20 genes&#x02019; genetic alterations in OV TCGA dataset</p></caption><graphic xlink:href="13048_2021_794_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec17"><title>Core gene validation</title><p id="Par37">To further verify the role of the top 20 genes, we performed the expression analysis of LMP tumors versus EOC in GSE12172 dataset. The results showed that all 20 hub genes were higher in EOC (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a). Meanwhile, ROC curve analysis was used to assess the capacity of these genes in differential diagnosis of LMP tumors and EOC in GSE12172, and almost all hub genes exhibited excellent diagnostic efficiency (AUC&#x02009;&#x0003e;&#x02009;0.90) except for CENPF (AUC&#x02009;=&#x02009;0.848) (Fig. <xref rid="Fig5" ref-type="fig">5</xref>b). Meanwhile, the prognostic value of the 20 genes for EOC was also assessed through the Kaplan-Meier plotter analysis. A prognostic forest map based on those genes is shown in Fig. <xref rid="Fig5" ref-type="fig">5</xref>c and 15 genes were significantly correlated to the overall survival (OS) of EOC patients. Moreover, EOC patients with higher levels of CCNB1 [HR&#x02009;=&#x02009;1.92 (1.55&#x02013;2.38), <italic>P</italic>&#x02009;=&#x02009;1.1E-09], KIF20A [HR&#x02009;=&#x02009;1.34 (1.14&#x02013;1.56), <italic>P</italic>&#x02009;=&#x02009;0.0003], ASPM [HR&#x02009;=&#x02009;1.33 (1.14&#x02013;1.55), <italic>P</italic>&#x02009;=&#x02009;0.0002], AURKA [HR&#x02009;=&#x02009;1.33 (1.17&#x02013;1.53), <italic>P</italic>&#x02009;=&#x02009;0.000029] and KIF23 [HR&#x02009;=&#x02009;1.31 (1.13&#x02013;1.52), <italic>P</italic>&#x02009;=&#x02009;0.0004] were significantly related to worse OS.
<fig id="Fig5"><label>Fig. 5</label><caption><p>Hub gene validation. <bold>a</bold> The expression of 20 genes in LMP tumors and EOC samples in GSE12172. ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001. <bold>b</bold> ROC curve analysis was performed to assess the capacity of 20 genes in differential diagnosis of LMP tumors and EOC. <bold>c</bold> Prognostic forest map of 20 genes in EOC patients</p></caption><graphic xlink:href="13048_2021_794_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec18"><title>Pearson correlation analysis between 5 core genes and immune checkpoint proteins</title><p id="Par38">Through above analysis, we screened the top 5 core genes (including CCNB1, KIF20A, ASPM, AURKA, and KIF23) with better diagnostic efficiency and higher prognostic value for EOC. To further explore the role of the 5 core genes, we used the GEPIA to assess the correlation between gene expression and different immune checkpoint proteins (PD-L1, PD-1, CTLA-4, TIGIT, LAG3 and TIM-3) in EOC samples. As shown in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>, CCNB1 had positive correlation with the LAG3 (R&#x02009;=&#x02009;0.11, <italic>p</italic>&#x02009;=&#x02009;0.027) and PD-L1 expression (R&#x02009;=&#x02009;0.11, <italic>p</italic>&#x02009;=&#x02009;0.021) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a &#x00026; b). KIF23 had positive correlation with PD-L1 expression (R&#x02009;=&#x02009;0.15, <italic>p</italic>&#x02009;=&#x02009;0.0025) (Fig. <xref rid="Fig6" ref-type="fig">6</xref>c). KIF20A had positive correlation with the PD-L1 expression (R&#x02009;=&#x02009;0.16, <italic>p</italic>&#x02009;=&#x02009;0.00097) (Fig. <xref rid="Fig6" ref-type="fig">6</xref>d). AURKA had positive correlation with the TIM-3 (R&#x02009;=&#x02009;0.13, <italic>p</italic>&#x02009;=&#x02009;0.0069) and LAG3 expression (R&#x02009;=&#x02009;0.14, <italic>p</italic>&#x02009;=&#x02009;0.0042) (Fig. <xref rid="Fig6" ref-type="fig">6</xref>e &#x00026; f). The above results indicate that four in five core genes are closely related to the EOC immunosuppressive microenvironment, which may explain that they could be used as effective prognostic markers for EOC.
<fig id="Fig6"><label>Fig. 6</label><caption><p>The positive correlation between the level of different immune checkpoint proteins and the expression of (<bold>a</bold> &#x00026; <bold>b</bold>) CCNB1, (<bold>c</bold>) KIF23, (<bold>d</bold>) KIF20A, (<bold>e</bold> &#x00026; <bold>f</bold>) AURKA in EOC</p></caption><graphic xlink:href="13048_2021_794_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec19"><title>Chemical-core gene network analysis</title><p id="Par39">Then, NetworkAnalyst was used to screen the related chemicals for the 5 core genes. Meanwhile, the chemical-core gene network was drawn with the software of Cytoscape. As shown in Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a, the interaction network includes 5 core genes and 300 chemicals. Moreover, we found that most chemicals were related to CCNB1 (degree score&#x02009;=&#x02009;246), AURKA (degree score&#x02009;=&#x02009;86), and KIF20A (degree score&#x02009;=&#x02009;67) (Table S<xref rid="MOESM2" ref-type="media">2</xref> and Fig. <xref rid="Fig7" ref-type="fig">7</xref>a), followed by ASPM (degree score&#x02009;=&#x02009;63) and KIF23 (degree score&#x02009;=&#x02009;52) via ranking the top 20 nodes in the network by cytoHubba. Furthermore, the top 15 chemicals screened by Cytoscape were found to be related with all five genes (Fig. <xref rid="Fig7" ref-type="fig">7</xref>b).
<fig id="Fig7"><label>Fig. 7</label><caption><p>Chemical-core gene network analysis. <bold>a</bold> Interaction network between core genes and chemicals. <bold>b</bold> The top 15 chemicals screened by Cytoscape were related to all five core genes. Core genes are displayed in red nodes, whereas related chemicals are shown in yellow and green nodes</p></caption><graphic xlink:href="13048_2021_794_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec20"><title>KEGG and GO pathway analysis for 5 core genes</title><p id="Par40">We also identified the potential function of these 5 core genes in EOC through KEGG and GO pathway analysis. In KEGG pathway analysis, we observed that &#x0201c;Cell cycle&#x0201d; was the key player in all 5 core genes (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a). Meanwhile, we investigated the previous 20 hub genes screened by cytoHubba for GO analysis by the application of ClueGO and CluePedia. As shown in Fig. <xref rid="Fig8" ref-type="fig">8</xref>b, all genes were involved in two different biological processes, including the nuclear division and chromosome condensation (Fig. <xref rid="Fig8" ref-type="fig">8</xref>b). Furthermore, we found that all 5 core genes were involved in nuclear division processes (Fig. <xref rid="Fig8" ref-type="fig">8</xref>c).
<fig id="Fig8"><label>Fig. 8</label><caption><p>KEGG and GO analysis of 5 core genes. <bold>a</bold> KEGG analysis for 5 core genes in OC. <bold>b</bold> GO biological process analysis of specific gene cluster. <bold>c</bold> A network of the GO analysis by ClueGo and CluePedia (all 5 core genes were highlighted red)</p></caption><graphic xlink:href="13048_2021_794_Fig8_HTML" id="MO8"/></fig></p></sec></sec><sec id="Sec21"><title>Discussion</title><p id="Par41">LMP, as a semi-malignant ovarian tumor, was identified by FIGO in 1971 and accounts for 15&#x02013;20% of epithelial ovarian tumors [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Moreover, LMP tumors often behave as a local epithelial lesions of the ovary [<xref ref-type="bibr" rid="CR18">18</xref>]. By comparison, EOC often shows strong invasive characteristics and represents about 70% of epithelial ovarian tumors [<xref ref-type="bibr" rid="CR6">6</xref>]. Thus, the prognosis of LMP and EOC differ considerably due to their different invasiveness. Additionally, the treatments of LMP and EOC are also signifi- cantly different. For EOC, total hysterectomy and bilateral salpingo-oophorectomy are the recommended surgical procedures and chemotherapy will also be administered to improve the curative effect [<xref ref-type="bibr" rid="CR7">7</xref>]. But for LMP, hysterectomy is the standard therapy and unilateral oophorectomy will also be considered in view of the patients&#x02019; desire to maintain fertility [<xref ref-type="bibr" rid="CR6">6</xref>]. However, although most LMP tumors will be in a mild state over a long period of time, a certain proportion of them display non-invasive extra-ovarian implants [<xref ref-type="bibr" rid="CR19">19</xref>]. And the accurate identification of LMP tumors is a continuously challenging and controversial field in gynecological pathology due to difficulty in accurate classification of implants [<xref ref-type="bibr" rid="CR20">20</xref>]. From this, accurate diagnosis of LMP and EOC is very important for the appropriate therapy selection and prognosis of patients, and the lack of accurate markers for distinguishing EOC from LMP will lead to incorrect diagnosis, inappropriate treatment and adverse consequences. In our study, we integrated three GEO databases and identified 234 DEGs between LMP and EOC samples, and further functional analysis was performed. The KEGG analysis displayed that the common up-regulated DEGs were mainly enriched in Cell cycle and Oocyte meiosis, while the common down-regulated genes were enriched in Huntington&#x02019;s disease. In addition, the GO analysis showed that the common up-regulated DEGs were mainly associated with Protein binding, Nucleoplasm and Nucleus, while the common downregulated genes were mainly associated with Cilium, Microtubule, and Motile cilium. In fact, many studies have shown that the Cell cycle [<xref ref-type="bibr" rid="CR21">21</xref>], Oocyte meiosis [<xref ref-type="bibr" rid="CR22">22</xref>], Protein binding [<xref ref-type="bibr" rid="CR23">23</xref>], Nucleoplasm [<xref ref-type="bibr" rid="CR24">24</xref>], Nucleus [<xref ref-type="bibr" rid="CR25">25</xref>], Microtubule [<xref ref-type="bibr" rid="CR26">26</xref>], Cilium and Motile cilium [<xref ref-type="bibr" rid="CR27">27</xref>] are closely related to EOC occurrence and development. However, the association between Huntington&#x02019;s disease and EOC still remains unclear. In brief, these functional enrichment results have certain guiding significance. Furthermore, a PPI network analysis was performed for the DEGs, and then the MCODE plug-in filtered out three related clusters. We further analyzed the function of cluster 1 and found that the results are consistent with the previous analysis. Next, the top 20 genes in PPI network were identified by CytoHubba plug-in. Subsequently, the GSE12172 dataset was used to further verify their expression in LMP and EOC samples, and the results showed that all 20 genes were higher expressed in EOC compared with LMP tumors, meaning that these genes may play a key role in EOC tumorigenesis. Meanwhile, ROC curve analysis revealed that all these genes had perfect diagnostic efficiency for differentiating EOC from LMP tumors. In addition, survival analysis of these 20 genes showed that 5 genes (CCNB1, KIF20A, ASPM, AURKA, and KIF23) were significantly related to a poorer OS in EOC patients, which may be partly attributed to the tumor immunosuppressive microenvironment when performing the Pearson correlation analysis between 5 core genes&#x02019; expression and the level of different immune checkpoint proteins. Then, NetworkAnalyst was applied to screen the chemicals that were associated with the 5 core genes and we found that CCNB1, AURKA, and KIF20A were clearly the three interactive core genes that link most chemicals. Moreover, the top 15 chemicals screened by Cytoscape were found to be related with all 5 genes. Among them, valproic acid [<xref ref-type="bibr" rid="CR28">28</xref>], Calcitriol [<xref ref-type="bibr" rid="CR29">29</xref>], cobaltous chloride [<xref ref-type="bibr" rid="CR30">30</xref>], Copper Sulfate [<xref ref-type="bibr" rid="CR31">31</xref>], Genistein [<xref ref-type="bibr" rid="CR32">32</xref>], 7,8-Dihydro-7,8-dihydroxybenzo(a) pyrene 9,10-oxide [<xref ref-type="bibr" rid="CR33">33</xref>], Methotrexate [<xref ref-type="bibr" rid="CR34">34</xref>], Mustard Gas [<xref ref-type="bibr" rid="CR35">35</xref>] and Cyclosporine [<xref ref-type="bibr" rid="CR36">36</xref>] all have been showed to have antitumor activity against EOC in vitro or vivo, whereas bisphenol A [<xref ref-type="bibr" rid="CR37">37</xref>], cadmium [<xref ref-type="bibr" rid="CR38">38</xref>], Aflatoxin B1 [<xref ref-type="bibr" rid="CR39">39</xref>] and Estradiol [<xref ref-type="bibr" rid="CR40">40</xref>] all have cancer-promoting activity in EOC. However, Lucanthone and Latex have not been studied in EOC till now despite they showed anti-cancer effects in other cancers [<xref ref-type="bibr" rid="CR41">41</xref>]. Thus, further clinical trials and studies are needed to identify and explore their impact on EOC in future.</p><p id="Par42">Next, the 5 core genes and their current researches in ovarian cancer were introduced as follows.</p><p id="Par43">CCNB1, also called Cyclin B1, is an important mitotic cyclin and produce complexes with p34(cdc2), which play a role in cell cycle [<xref ref-type="bibr" rid="CR42">42</xref>]. Meanwhile, CCNB1 has been shown to be over expressed in a variety of tumors, including EOC [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], and many studies have also demonstrated that cyclin B1 is involved in the differentiation, proliferation, metastasis and chemoresistance of ovarian cancer cell [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par44">KIF20A, is a microtubule-associated motor protein localized to the Golgi apparatus that is required for cell cycle mitosis [<xref ref-type="bibr" rid="CR47">47</xref>]. Until now, KIF20A has been reported to be a key gene in the progression of many tumors, such as prostate cancer, colorectal cancer, gastric cancer, et al. [<xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>]. Recently, KIF20A has also been proved to promote the invasion and metastasis of EOC, and could be seen as a valuable chemoresistance and prognostic biomarker for EOC patients [<xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par45">ASPM (abnormal spindle-like microcephaly associated) was originally seen as a centrosomal protein regulating neurogenesis [<xref ref-type="bibr" rid="CR54">54</xref>]. In addition, ASPM is also known to regulate mitosis through controlling microtubule disassembly and is widely highly-expressed in a wide range of malignant tumors, including EOC [<xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par46">AURKA, as a family of serine/threonine kinases, localizes in mitotic spindles and centrosomes where it mediates mitotic process and chromosome stability [<xref ref-type="bibr" rid="CR60">60</xref>]. Mounting evidence have shown that AURKA is involved in the tumorigenesis and progression of multiple types of cancer including solid and hematological malignancies [<xref ref-type="bibr" rid="CR61">61</xref>&#x02013;<xref ref-type="bibr" rid="CR63">63</xref>]. Meanwhile, a certain quantity of AURKA kinase inhibitors have been developed during the past decade, which suppress cancer cell proliferation, migration and invasion [<xref ref-type="bibr" rid="CR61">61</xref>]. In our study, we identified several chemicals related with AURKA that against EOC, which may contribute to the development of novel potential drugs for the treatment of EOC.</p><p id="Par47">KIF23, is a member of kinesin motor protein that regulates mitosis and cytokinesis [<xref ref-type="bibr" rid="CR64">64</xref>]. KIF23 overexpression has been found in breast cancer, pancreatic cancer, primary lung cancer and prostate cancer, and also has been related with poor prognosis for several cancer types [<xref ref-type="bibr" rid="CR65">65</xref>&#x02013;<xref ref-type="bibr" rid="CR68">68</xref>]. Recently, Tong Lia et al. has found that KIF23 was mainly related to cell cycle, and indicated a poor prognosis in EOC patients. Meanwhile, they also found that both miR-503-5p and miR-424-5p could directly targeted KIF23 to inhibit OC development in vitro [<xref ref-type="bibr" rid="CR69">69</xref>]. Additionally, Hu Y et al. has reported that KIF23 could not only be used as a prognostic indicator for EOC, but also had a positive correlation with immune checkpoint protein, suggesting that it can be performed as a potential target for cancer immunotherapy, which is consistent with the results of our study [<xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par48">Although above studies have found that these 5 genes related to the diagnosis, treatment, and prognosis of EOC, the molecular mechanisms of EOC tumorigenesis still remain unclear. In order to further understand the biological functions of these 5 genes in EOC, we performed the KEGG and GO pathway analysis for them. As a result, we observed that all 5 core genes were mainly enriched in &#x0201c;Cell cycle&#x0201d;, consistent with our previous pathway analysis of up-regulated DEGs in EOC. The results also demonstrate that all 5 core genes have potential value as targets of chemotherapy drugs for EOC, which is based on a universally accepted fact that most of the chemotherapeutic drugs are developed according to their regulation of cell cycle process.</p></sec><sec id="Sec22"><title>Conclusions</title><p id="Par49">In brief, by performing an integrated bioinformatic analysis of three GEO datasets, we identified five core genes with better diagnostic efficiency and higher prognostic value for EOC and we also screened the potential drugs or risk factors for EOC through chemical-core gene network analysis base on them. Moreover, we found that all five core genes mainly regulate EOC development via the cell cycle pathway through the KEGG and GO pathway analysis. However, there are still a few limitations in our study. Since the study is based on data analysis, a large number of clinical samples and biological experiments are urgently needed to verify the results before promoting the clinical application of all five core genes as diagnostic and prognostic indicators or therapeutic targets in future.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec23"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13048_2021_794_MOESM1_ESM.xlsx"><caption><p><bold>Additional file 1: Table S1.</bold> Top 20 hub genes screened by cytoHubba according to MCC.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13048_2021_794_MOESM2_ESM.xlsx"><caption><p><bold>Additional file 2: Table S2.</bold> Top 15 related chemicals screened by cytoHubba according to MCC.</p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>EOC</term><def><p id="Par5">Epithelial ovarian cancer</p></def></def-item><def-item><term>LMP</term><def><p id="Par6">Ovarian low malignant potential tumors</p></def></def-item><def-item><term>GO</term><def><p id="Par7">Gene Ontology</p></def></def-item><def-item><term>KEGG</term><def><p id="Par8">Kyoto Encyclopedia of Gene and Genome</p></def></def-item><def-item><term>PPI</term><def><p id="Par9">Protein&#x02013;protein interaction</p></def></def-item><def-item><term>DEGs</term><def><p id="Par10">Differentially expressed genes</p></def></def-item><def-item><term>MCODE</term><def><p id="Par11">Molecular complex detection;</p></def></def-item><def-item><term>MCC</term><def><p id="Par12">Maximal Clique Centrality</p></def></def-item><def-item><term>HR</term><def><p id="Par13">Hazard ratio</p></def></def-item><def-item><term>OS</term><def><p id="Par14">Overall survival</p></def></def-item><def-item><term>GEO</term><def><p id="Par15">Gene expression omnibus</p></def></def-item><def-item><term>ROC</term><def><p id="Par16">Receiver operating characteristic</p></def></def-item><def-item><term>TCGA</term><def><p id="Par17">The Cancer Genome Atlas</p></def></def-item><def-item><term>FIGO</term><def><p id="Par18">International Federation of Gynecology and Obstetrics</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>The authors sincerely thank the researchers for providing their GEO databases information online. Meanwhile, we thank the Research Square (a preprint platform) for including this manuscript as a preprint.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>WH designed the study and drafted the manuscript. HZ and JG performed the data collecting and analysis. ZL, JL, QC, YG and MR participated in the data interpretation. As the corresponding authors, WY and XZ was responsible for critical revision of the manuscript and final decision to submit the article for publication. The authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by Beijing Municipal Science &#x00026; Technology Commission (grant number: Z181100001718193) and The National Natural Science Foundation of China (grant numbers: 81672838 and 61431019).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The datasets generated and analyzed during the current study are available from TCGA and GEO database.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par50">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par51">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par52">The authors declare that they have no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Layton</surname><given-names>O</given-names></name><name><surname>Hong</surname><given-names>L</given-names></name></person-group><article-title>Identification of Genes and Pathways Involved in Ovarian Epithelial Cancer by Bioinformatics Analysis</article-title><source>J Cancer</source><year>2018</year><volume>9</volume><fpage>3016</fpage><pub-id pub-id-type="doi">10.7150/jca.26133</pub-id><?supplied-pmid 30210623?><pub-id pub-id-type="pmid">30210623</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maringe</surname><given-names>C</given-names></name><name><surname>Walters</surname><given-names>S</given-names></name><name><surname>Butler</surname><given-names>J</given-names></name><name><surname>Coleman</surname><given-names>MP</given-names></name><name><surname>Hacker</surname><given-names>N</given-names></name><name><surname>Hanna</surname><given-names>L</given-names></name><etal/></person-group><article-title>Stage at diagnosis and ovarian cancer survival: evidence from the international Cancer benchmarking partnership</article-title><source>Gynecol Oncol</source><year>2012</year><volume>127</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2012.06.033</pub-id><?supplied-pmid 22750127?><pub-id pub-id-type="pmid">22750127</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Vecchia</surname><given-names>C</given-names></name></person-group><article-title>Ovarian cancer: epidemiology and risk factors</article-title><source>Eur J Cancer Prev</source><year>2017</year><volume>26</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1097/CEJ.0000000000000217</pub-id><?supplied-pmid 26731563?><pub-id pub-id-type="pmid">26731563</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seong</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>MK</given-names></name><name><surname>Song</surname><given-names>T</given-names></name></person-group><article-title>Controversies in borderline ovarian tumors</article-title><source>J Gynecol Oncol</source><year>2015</year><volume>26</volume><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.3802/jgo.2015.26.4.343</pub-id><?supplied-pmid 26404125?><pub-id pub-id-type="pmid">26404125</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hanna</surname><given-names>RK</given-names></name><name><surname>Soper</surname><given-names>JT</given-names></name><name><surname>Notes</surname><given-names>P</given-names></name><name><surname>Livasy</surname><given-names>C</given-names></name></person-group><source>Ovarian Tumors of Low Malignant Potential</source><year>2010</year><fpage>110</fpage><lpage>120</lpage></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Ian</surname><given-names>S</given-names></name><name><surname>Lok</surname><given-names>S</given-names></name><name><surname>Sze</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>T</given-names></name><etal/></person-group><article-title>FAM83D promotes ovarian cancer progression and its potential application in diagnosis of invasive ovarian cancer</article-title><source>J Cell Mol Med</source><year>2019</year><volume>23</volume><fpage>4569</fpage><lpage>4581</lpage><pub-id pub-id-type="doi">10.1111/jcmm.14360</pub-id><?supplied-pmid 31037837?><pub-id pub-id-type="pmid">31037837</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aluloski</surname><given-names>I</given-names></name><name><surname>Tanturovski</surname><given-names>M</given-names></name><name><surname>Jovanovic</surname><given-names>R</given-names></name><name><surname>Kostadinova-Kunovska</surname><given-names>S</given-names></name><name><surname>Petrusevska</surname><given-names>G</given-names></name><name><surname>Stojkovski</surname><given-names>I</given-names></name><name><surname>Petreska</surname><given-names>B</given-names></name></person-group><article-title>Survival of advanced stage high-grade serous ovarian Cancer patients in the republic of Macedonia</article-title><source>Open Access Macedonian J Med Sci</source><year>2017</year><volume>5</volume><fpage>904</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.3889/oamjms.2017.215</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Shan</surname><given-names>W</given-names></name><etal/></person-group><article-title>Identification of Potential Biomarkers in Association With Progression and Prognosis in Epithelial Ovarian Cancer by Integrated Bioinformatics Analysis</article-title><source>Front Genet</source><year>2019</year><volume>10</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.3389/fgene.2019.01031</pub-id><?supplied-pmid 30804975?><pub-id pub-id-type="pmid">30804975</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><etal/></person-group><article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><fpage>e47</fpage><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><?supplied-pmid 25605792?><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Franceschini</surname><given-names>A</given-names></name><name><surname>Wyder</surname><given-names>S</given-names></name><name><surname>Forslund</surname><given-names>K</given-names></name><name><surname>Heller</surname><given-names>D</given-names></name><name><surname>Huerta-Cepas</surname><given-names>J</given-names></name><etal/></person-group><article-title>STRING v10: protein-protein interaction networks, integrated over the tree of life</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><fpage>D447</fpage><lpage>D452</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1003</pub-id><?supplied-pmid 25352553?><pub-id pub-id-type="pmid">25352553</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>C-H</given-names></name><name><surname>Chen</surname><given-names>S-H</given-names></name><name><surname>Wu</surname><given-names>H-H</given-names></name><name><surname>Ho</surname><given-names>C-W</given-names></name><name><surname>Ko</surname><given-names>M-T</given-names></name><name><surname>Lin</surname><given-names>C-Y</given-names></name></person-group><article-title>cytoHubba: identifying hub objects and sub-networks from complex interactome</article-title><source>BMC Syst Biol</source><year>2014</year><volume>8</volume><issue>Suppl 4</issue><fpage>S11</fpage><pub-id pub-id-type="doi">10.1186/1752-0509-8-S4-S11</pub-id><?supplied-pmid 25521941?><pub-id pub-id-type="pmid">25521941</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Chen L, Zhao T. Identification of KHSRP-regulated RNAs in esophagus Cancer by integrated bioinformatics analysis. Cancer Biother Radiopharm. 2020. 10.1089/cbr.2020.3745.</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Soufan</surname><given-names>O</given-names></name><name><surname>Ewald</surname><given-names>J</given-names></name><name><surname>Hancock</surname><given-names>REW</given-names></name><name><surname>Basu</surname><given-names>N</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name></person-group><article-title>NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><fpage>W234</fpage><lpage>W241</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz240</pub-id><?supplied-pmid 30931480?><pub-id pub-id-type="pmid">30931480</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindea</surname><given-names>G</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Hackl</surname><given-names>H</given-names></name><name><surname>Charoentong</surname><given-names>P</given-names></name><name><surname>Tosolini</surname><given-names>M</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><etal/></person-group><article-title>ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks</article-title><source>Bioinformatics (Oxford, England)</source><year>2009</year><volume>25</volume><fpage>1091</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp101</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindea</surname><given-names>G</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name></person-group><article-title>CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data</article-title><source>Bioinformatics (Oxford, England)</source><year>2013</year><volume>29</volume><fpage>661</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt019</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kottmeier</surname><given-names>HL</given-names></name></person-group><article-title>Classification and staging of malignant tumours in the female pelvis</article-title><source>Acta Obstet Gynecol Scand</source><year>1971</year><volume>50</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.3109/00016347109157278</pub-id><pub-id pub-id-type="pmid">5558593</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sk&#x000ed;rnisd&#x000f3;ttir</surname><given-names>I</given-names></name><name><surname>Garmo</surname><given-names>H</given-names></name><name><surname>Wilander</surname><given-names>E</given-names></name><name><surname>Holmberg</surname><given-names>L</given-names></name></person-group><article-title>Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer</article-title><source>Int J Cancer</source><year>2008</year><volume>123</volume><fpage>1897</fpage><lpage>1901</lpage><pub-id pub-id-type="doi">10.1002/ijc.23724</pub-id><?supplied-pmid 18661518?><pub-id pub-id-type="pmid">18661518</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischerova</surname><given-names>D</given-names></name><name><surname>Zikan</surname><given-names>M</given-names></name><name><surname>Dundr</surname><given-names>P</given-names></name><name><surname>Cibula</surname><given-names>D</given-names></name></person-group><article-title>Diagnosis, treatment, and follow-up of borderline ovarian tumors</article-title><source>Oncologist</source><year>2012</year><volume>17</volume><fpage>1515</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2012-0139</pub-id><?supplied-pmid 23024155?><pub-id pub-id-type="pmid">23024155</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadron</surname><given-names>I</given-names></name><name><surname>Leunen</surname><given-names>K</given-names></name><name><surname>Van Gorp</surname><given-names>T</given-names></name><name><surname>Amant</surname><given-names>F</given-names></name><name><surname>Neven</surname><given-names>P</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name></person-group><article-title>Management of borderline ovarian neoplasms</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>20</issue><fpage>2928</fpage><lpage>2937</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.10.8076</pub-id><?supplied-pmid 17617524?><pub-id pub-id-type="pmid">17617524</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukumoto</surname><given-names>M</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name></person-group><article-title>Ovarian epithelial tumors of low malignant potential : are they precursors of ovarian carcinoma ?</article-title><source>Potential</source><year>2006</year><volume>1</volume><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1827.2006.01960.x</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivy</surname><given-names>SP</given-names></name><name><surname>Kunos</surname><given-names>CA</given-names></name><name><surname>Arnaldez</surname><given-names>FI</given-names></name><name><surname>Kohn</surname><given-names>EC</given-names></name></person-group><article-title>Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints</article-title><source>Expert Opin Investig Drugs</source><year>2019</year><volume>28</volume><fpage>771</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1080/13543784.2019.1657403</pub-id><?supplied-pmid 31449760?><pub-id pub-id-type="pmid">31449760</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><etal/></person-group><article-title>Identification of core genes in ovarian cancer by an integrative meta-analysis</article-title><source>J Ovarian Res</source><year>2018</year><volume>11</volume><fpage>94</fpage><pub-id pub-id-type="doi">10.1186/s13048-018-0467-z</pub-id><?supplied-pmid 30453999?><pub-id pub-id-type="pmid">30453999</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z-G</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>X-F</given-names></name><name><surname>Su</surname><given-names>X-J</given-names></name></person-group><article-title>Poly r(C) binding protein 1 regulates posttranscriptional expression of the ubiquitin ligase TRIM56 in ovarian Cancer</article-title><source>IUBMB Life</source><year>2019</year><volume>71</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1002/iub.1948</pub-id><?supplied-pmid 30281912?><pub-id pub-id-type="pmid">30281912</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brachner</surname><given-names>A</given-names></name><name><surname>Foisner</surname><given-names>R</given-names></name></person-group><article-title>Lamina-associated polypeptide (LAP)2&#x003b1; and other LEM proteins in cancer biology</article-title><source>Adv Exp Med Biol</source><year>2014</year><volume>773</volume><fpage>143</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1007/978-1-4899-8032-8_7</pub-id><?supplied-pmid 24563347?><pub-id pub-id-type="pmid">24563347</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>P-H</given-names></name><name><surname>Hung</surname><given-names>S-H</given-names></name><name><surname>Ren</surname><given-names>T</given-names></name><name><surname>Shih</surname><given-names>I-M</given-names></name><name><surname>Tseng</surname><given-names>Y</given-names></name></person-group><article-title>Cell cycle-dependent alteration in NAC1 nuclear body dynamics and morphology</article-title><source>Phys Biol</source><year>2011</year><volume>8</volume><fpage>15005</fpage><pub-id pub-id-type="doi">10.1088/1478-3975/8/1/015005</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrail</surname><given-names>DJ</given-names></name><name><surname>Khambhati</surname><given-names>NN</given-names></name><name><surname>Qi</surname><given-names>MX</given-names></name><name><surname>Patel</surname><given-names>KS</given-names></name><name><surname>Ravikumar</surname><given-names>N</given-names></name><name><surname>Brandenburg</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Alterations in ovarian cancer cell adhesion drive taxol resistance by increasing microtubule dynamics in a FAK-dependent manner</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>9529</fpage><pub-id pub-id-type="doi">10.1038/srep09529</pub-id><?supplied-pmid 25886093?><pub-id pub-id-type="pmid">25886093</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohozinski</surname><given-names>J</given-names></name><name><surname>Diaz-Arrastia</surname><given-names>C</given-names></name><name><surname>Edwards</surname><given-names>CL</given-names></name></person-group><article-title>Do some epithelial ovarian cancers originate from a fallopian tube ciliate cell lineage?</article-title><source>Med Hypotheses</source><year>2017</year><volume>107</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2017.07.014</pub-id><?supplied-pmid 28915954?><pub-id pub-id-type="pmid">28915954</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sajadpoor</surname><given-names>Z</given-names></name><name><surname>Amini-Farsani</surname><given-names>Z</given-names></name><name><surname>Teimori</surname><given-names>H</given-names></name><name><surname>Shamsara</surname><given-names>M</given-names></name><name><surname>Sangtarash</surname><given-names>MH</given-names></name><name><surname>Ghasemi-Dehkordi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Valproic acid promotes apoptosis and Cisplatin sensitivity through Downregulation of H19 noncoding RNA in ovarian A2780 cells</article-title><source>Appl Biochem Biotechnol</source><year>2018</year><volume>185</volume><fpage>1132</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1007/s12010-017-2684-0</pub-id><?supplied-pmid 29468525?><pub-id pub-id-type="pmid">29468525</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeung</surname><given-names>TL</given-names></name><name><surname>Sheng</surname><given-names>J</given-names></name><name><surname>Leung</surname><given-names>CS</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>SY</given-names></name></person-group><article-title>Systematic identification of druggable epithelial-stromal crosstalk signaling networks in ovarian cancer</article-title><source>J Natl Cancer Inst</source><year>2019</year><volume>111</volume><fpage>272</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1093/jnci/djy097</pub-id><?supplied-pmid 29860390?><pub-id pub-id-type="pmid">29860390</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Chattopadhyay</surname><given-names>A</given-names></name><name><surname>Navab</surname><given-names>M</given-names></name><name><surname>Grijalva</surname><given-names>V</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Fogelman</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1&#x003b1; in human ovarian cancer cell lines and a mouse ovarian cancer model</article-title><source>J Pharmacol Exp Ther</source><year>2012</year><volume>342</volume><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1124/jpet.112.191544</pub-id><?supplied-pmid 22537771?><pub-id pub-id-type="pmid">22537771</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burki</surname><given-names>HR</given-names></name><name><surname>Okita</surname><given-names>GT</given-names></name></person-group><article-title>Effect of oral copper sulfate on 7,12-dimethylbenz (alpha) anthracene carcinogenesis in mice</article-title><source>Br J Cancer</source><year>1969</year><volume>23</volume><fpage>591</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1038/bjc.1969.73</pub-id><?supplied-pmid 5360335?><pub-id pub-id-type="pmid">5360335</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>K</given-names></name><name><surname>Quan</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name></person-group><article-title>Genistein inhibits stemness of SKOV3 cells induced by macrophages co-cultured with ovarian cancer stem-like cells through IL-8/STAT3 axis</article-title><source>J Exp Clin Cancer Res</source><year>2019</year><volume>38</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/s13046-018-1010-1</pub-id><?supplied-pmid 30646963?><pub-id pub-id-type="pmid">30646963</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeffy</surname><given-names>BD</given-names></name><name><surname>Schultz</surname><given-names>EU</given-names></name><name><surname>Selmin</surname><given-names>O</given-names></name><name><surname>Gudas</surname><given-names>JM</given-names></name><name><surname>Bowden</surname><given-names>GT</given-names></name><name><surname>Romagnolo</surname><given-names>D</given-names></name></person-group><article-title>Inhibition of BRCA-1 expression by benzo [a] pyrene and its diol epoxide</article-title><source>Mol Carcinog</source><year>1999</year><volume>26</volume><fpage>100</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1002/(sici)1098-2744(199910)26:2&#x0003c;100::aid-mc5&#x0003e;3.0.co;2-1</pub-id><?supplied-pmid 10506754?><pub-id pub-id-type="pmid">10506754</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pantshwa</surname><given-names>JM</given-names></name><name><surname>Rhoda</surname><given-names>K</given-names></name><name><surname>Clift</surname><given-names>SJ</given-names></name><name><surname>Pradeep</surname><given-names>P</given-names></name><name><surname>Choonara</surname><given-names>YE</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><etal/></person-group><article-title>Chemotherapeutic efficacy of implantable antineoplastic-treatment protocols in an optimal mouse model for human ovarian carcinoma cell targeting</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.3390/ijms19103030</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>P</given-names></name><name><surname>Sundaram</surname><given-names>C</given-names></name><name><surname>Jhurani</surname><given-names>S</given-names></name><name><surname>Kunnumakkara</surname><given-names>AB</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Curcumin and cancer: an &#x000ab;old-age&#x000bb; disease with an &#x000ab;age-old&#x000bb; solution</article-title><source>Cancer Lett</source><year>2008</year><volume>267</volume><fpage>133</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2008.03.025</pub-id><?supplied-pmid 18462866?><pub-id pub-id-type="pmid">18462866</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name></person-group><article-title>Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin a and low-intensity ultrasound</article-title><source>Eur J Pharm Biopharm</source><year>2015</year><volume>91</volume><fpage>103</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2015.02.003</pub-id><?supplied-pmid 25668779?><pub-id pub-id-type="pmid">25668779</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Low dose of Bisphenol a modulates ovarian Cancer gene expression profile and promotes epithelial to Mesenchymal transition via canonical Wnt pathway</article-title><source>Toxicol Sci</source><year>2018</year><volume>164</volume><fpage>527</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfy107</pub-id><?supplied-pmid 29718440?><pub-id pub-id-type="pmid">29718440</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksen</surname><given-names>KT</given-names></name><name><surname>Halkj&#x000e6;r</surname><given-names>J</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>M</given-names></name><name><surname>Meliker</surname><given-names>JR</given-names></name><name><surname>McElroy</surname><given-names>JA</given-names></name><name><surname>Tj&#x000f8;nneland</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dietary cadmium intake and risk of breast, endometrial and ovarian cancer in Danish postmenopausal women: a prospective cohort study</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e100815</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0100815</pub-id><?supplied-pmid 24963789?><pub-id pub-id-type="pmid">24963789</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0017b;o&#x00142;nierczyk</surname><given-names>AK</given-names></name><name><surname>M&#x00105;czka</surname><given-names>WK</given-names></name><name><surname>Grabarczyk</surname><given-names>M</given-names></name><name><surname>Wi&#x00144;ska</surname><given-names>K</given-names></name><name><surname>Wo&#x0017a;niak</surname><given-names>E</given-names></name><name><surname>Anio&#x00142;</surname><given-names>M</given-names></name></person-group><article-title>Isoxanthohumol--biologically active hop flavonoid</article-title><source>Fitoterapia</source><year>2015</year><volume>103</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2015.03.007</pub-id><?supplied-pmid 25771121?><pub-id pub-id-type="pmid">25771121</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valladares</surname><given-names>M</given-names></name><name><surname>Plaza-Parrochia</surname><given-names>F</given-names></name><name><surname>L&#x000e9;pez</surname><given-names>M</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>D</given-names></name><name><surname>Gabler</surname><given-names>F</given-names></name><name><surname>Gayan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effect of estradiol on the expression of angiogenic factors in epithelial ovarian cancer</article-title><source>Histol Histopathol</source><year>2017</year><volume>32</volume><fpage>1187</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.14670/HH-11-874</pub-id><?supplied-pmid 28116735?><pub-id pub-id-type="pmid">28116735</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carew</surname><given-names>JS</given-names></name><name><surname>Espitia</surname><given-names>CM</given-names></name><name><surname>Esquivel</surname><given-names>JA</given-names><suffix>2nd</suffix></name><name><surname>Mahalingam</surname><given-names>D</given-names></name><name><surname>Kelly</surname><given-names>KR</given-names></name><name><surname>Reddy</surname><given-names>G</given-names></name><etal/></person-group><article-title>Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>6602</fpage><lpage>6613</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.151324</pub-id><?supplied-pmid 21148553?><pub-id pub-id-type="pmid">21148553</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Yoshimi</surname><given-names>N</given-names></name><name><surname>Ino</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name></person-group><article-title>Overexpression of cyclin B1 in human colorectal cancers</article-title><source>J Cancer Res Clin Oncol</source><year>1997</year><volume>123</volume><fpage>124</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1007/BF01269891</pub-id><?supplied-pmid 9030252?><pub-id pub-id-type="pmid">9030252</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Gonzalez-Angulo</surname><given-names>A-M</given-names></name><name><surname>Myhre</surname><given-names>S</given-names></name><name><surname>Carey</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>J-S</given-names></name><name><surname>Overgaard</surname><given-names>J</given-names></name><etal/></person-group><article-title>Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>3654</fpage><lpage>3662</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-3293</pub-id><?supplied-pmid 19470724?><pub-id pub-id-type="pmid">19470724</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J-Q</given-names></name><name><surname>Kubo</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Usuki</surname><given-names>H</given-names></name><name><surname>Fujita</surname><given-names>J</given-names></name><name><surname>Bandoh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cyclin B1, unlike cyclin G1, increases significantly during colorectal carcinogenesis and during later metastasis to lymph nodes</article-title><source>Int J Oncol</source><year>2003</year><volume>22</volume><fpage>1101</fpage><lpage>1110</lpage><?supplied-pmid 12684677?><pub-id pub-id-type="pmid">12684677</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fei</surname><given-names>F</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The subcellular location of cyclin B1 and CDC25 associated with the formation of polyploid giant cancer cells and their clinicopathological significance</article-title><source>Lab Investig</source><year>2019</year><volume>99</volume><fpage>483</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1038/s41374-018-0157-x</pub-id><?supplied-pmid 30487595?><pub-id pub-id-type="pmid">30487595</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TMH</given-names></name><name><surname>Shin</surname><given-names>I-W</given-names></name><name><surname>Lee</surname><given-names>TJ</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer</article-title><source>Gynecol Oncol</source><year>2016</year><volume>140</volume><fpage>545</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2015.12.006</pub-id><?supplied-pmid 26691219?><pub-id pub-id-type="pmid">26691219</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>G-R</given-names></name><name><surname>Zou</surname><given-names>F-Y</given-names></name><name><surname>Dang</surname><given-names>B-L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Genistein-induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study</article-title><source>Proteomics</source><year>2012</year><volume>12</volume><fpage>2391</fpage><lpage>2399</lpage><pub-id pub-id-type="doi">10.1002/pmic.201100652</pub-id><?supplied-pmid 22887948?><pub-id pub-id-type="pmid">22887948</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Chai</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><etal/></person-group><article-title>Aberrant KIF20A expression is associated with adverse clinical outcome and promotes tumor progression in prostate Cancer</article-title><source>Dis Markers</source><year>2019</year><volume>2019</volume><fpage>4782730</fpage><pub-id pub-id-type="doi">10.1155/2019/4782730</pub-id><?supplied-pmid 31565099?><pub-id pub-id-type="pmid">31565099</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>M</given-names></name><name><surname>Zhuang</surname><given-names>K</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>KIF20A promotes cellular malignant behavior and enhances resistance to chemotherapy in colorectal cancer through regulation of the JAK/STAT3 signaling pathway</article-title><source>Aging</source><year>2019</year><volume>11</volume><fpage>11905</fpage><lpage>11921</lpage><pub-id pub-id-type="doi">10.18632/aging.102505</pub-id><?supplied-pmid 31841120?><pub-id pub-id-type="pmid">31841120</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Hong</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Upregulation of KIF20A correlates with poor prognosis in gastric cancer</article-title><source>Cancer Manag Res</source><year>2018</year><volume>10</volume><fpage>6205</fpage><lpage>6216</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S176147</pub-id><?supplied-pmid 30538567?><pub-id pub-id-type="pmid">30538567</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Bu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Cyclin F and KIF20A, FOXM1 target genes, increase proliferation and invasion of ovarian cancer cells</article-title><source>Exp Cell Res</source><year>2020</year><volume>395</volume><fpage>112212</fpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2020.112212</pub-id><?supplied-pmid 32771525?><pub-id pub-id-type="pmid">32771525</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Niu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Overexpression of kinesin family member 20A is associated with unfavorable clinical outcome and tumor progression in epithelial ovarian cancer</article-title><source>Cancer Manag Res</source><year>2018</year><volume>10</volume><fpage>3433</fpage><lpage>3450</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S169214</pub-id><?supplied-pmid 30254487?><pub-id pub-id-type="pmid">30254487</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>Y</given-names></name><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Sakata</surname><given-names>J</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Utsumi</surname><given-names>F</given-names></name><name><surname>Niimi</surname><given-names>K</given-names></name><etal/></person-group><article-title>KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clear-cell carcinoma cells</article-title><source>Oncol Rep</source><year>2018</year><volume>40</volume><fpage>195</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.3892/or.2018.6401</pub-id><?supplied-pmid 29749467?><pub-id pub-id-type="pmid">29749467</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouprina</surname><given-names>N</given-names></name><name><surname>Pavlicek</surname><given-names>A</given-names></name><name><surname>Collins</surname><given-names>NK</given-names></name><name><surname>Nakano</surname><given-names>M</given-names></name><name><surname>Noskov</surname><given-names>VN</given-names></name><name><surname>Ohzeki</surname><given-names>J-I</given-names></name><etal/></person-group><article-title>The microcephaly ASPM gene is expressed in proliferating tissues and encodes for a mitotic spindle protein</article-title><source>Hum Mol Genet</source><year>2005</year><volume>14</volume><fpage>2155</fpage><lpage>2165</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddi220</pub-id><?supplied-pmid 15972725?><pub-id pub-id-type="pmid">15972725</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Rezabkova</surname><given-names>L</given-names></name><name><surname>Hua</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Capitani</surname><given-names>G</given-names></name><name><surname>Altelaar</surname><given-names>AFM</given-names></name><etal/></person-group><article-title>Microtubule minus-end regulation at spindle poles by an ASPM-katanin complex</article-title><source>Nat Cell Biol</source><year>2017</year><volume>19</volume><fpage>480</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/ncb3511</pub-id><?supplied-pmid 28436967?><pub-id pub-id-type="pmid">28436967</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S-Y</given-names></name><name><surname>Pan</surname><given-names>H-W</given-names></name><name><surname>Liu</surname><given-names>S-H</given-names></name><name><surname>Jeng</surname><given-names>Y-M</given-names></name><name><surname>Hu</surname><given-names>F-C</given-names></name><name><surname>Peng</surname><given-names>S-Y</given-names></name><etal/></person-group><article-title>ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>4814</fpage><lpage>4820</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-5262</pub-id><?supplied-pmid 18676753?><pub-id pub-id-type="pmid">18676753</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>C-C</given-names></name><name><surname>Liao</surname><given-names>W-Y</given-names></name><name><surname>Chan</surname><given-names>T-S</given-names></name><name><surname>Chen</surname><given-names>W-Y</given-names></name><name><surname>Lee</surname><given-names>C-T</given-names></name><name><surname>Shan</surname><given-names>Y-S</given-names></name><etal/></person-group><article-title>The differential distributions of ASPM isoforms and their roles in Wnt signaling, cell cycle progression, and pancreatic cancer prognosis</article-title><source>J Pathol</source><year>2019</year><volume>249</volume><fpage>498</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1002/path.5341</pub-id><?supplied-pmid 31465125?><pub-id pub-id-type="pmid">31465125</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y-J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Yin</surname><given-names>Z-Z</given-names></name><name><surname>Yuan</surname><given-names>Z-Y</given-names></name><name><surname>Xu</surname><given-names>L-M</given-names></name></person-group><article-title>Abnormal spindle-like microcephaly-associated protein (ASPM) contributes to the progression of lung squamous cell carcinoma (LSCC) by regulating CDK4</article-title><source>J Cancer</source><year>2020</year><volume>11</volume><issue>18</issue><fpage>5413</fpage><lpage>5423</lpage><pub-id pub-id-type="doi">10.7150/jca.39760</pub-id><?supplied-pmid 32742488?><pub-id pub-id-type="pmid">32742488</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Br&#x000fc;ning-Richardson</surname><given-names>A</given-names></name><name><surname>Bond</surname><given-names>J</given-names></name><name><surname>Alsiary</surname><given-names>R</given-names></name><name><surname>Richardson</surname><given-names>J</given-names></name><name><surname>Cairns</surname><given-names>DA</given-names></name><name><surname>McCormack</surname><given-names>L</given-names></name><etal/></person-group><article-title>ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival</article-title><source>Br J Cancer</source><year>2011</year><volume>104</volume><fpage>1602</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.117</pub-id><?supplied-pmid 21505456?><pub-id pub-id-type="pmid">21505456</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautschi</surname><given-names>O</given-names></name><name><surname>Heighway</surname><given-names>J</given-names></name><name><surname>Mack</surname><given-names>PC</given-names></name><name><surname>Purnell</surname><given-names>PR</given-names></name><name><surname>Lara</surname><given-names>PNJ</given-names></name><name><surname>Gandara</surname><given-names>DR</given-names></name></person-group><article-title>Aurora kinases as anticancer drug targets</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>1639</fpage><lpage>1648</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-2179</pub-id><?supplied-pmid 18347165?><pub-id pub-id-type="pmid">18347165</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name></person-group><article-title>Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy</article-title><source>Mol Cancer</source><year>2021</year><volume>20</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s12943-020-01305-3</pub-id><?supplied-pmid 33451333?><pub-id pub-id-type="pmid">33451333</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Do</surname><given-names>T-V</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Bickel</surname><given-names>LE</given-names></name><name><surname>Klein-Szanto</surname><given-names>AJ</given-names></name><name><surname>Pathak</surname><given-names>HB</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name><etal/></person-group><article-title>Aurora kinase a mediates epithelial ovarian cancer cell migration and adhesion</article-title><source>Oncogene</source><year>2014</year><volume>33</volume><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.632</pub-id><?supplied-pmid 23334327?><pub-id pub-id-type="pmid">23334327</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Qin</surname><given-names>D</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name></person-group><article-title>Effect of AURKA gene expression knockdown on angiogenesis and tumorigenesis of human ovarian cancer cell lines</article-title><source>Target Oncol</source><year>2016</year><volume>11</volume><fpage>771</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1007/s11523-016-0436-7</pub-id><?supplied-pmid 27250762?><pub-id pub-id-type="pmid">27250762</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nislow</surname><given-names>C</given-names></name><name><surname>Lombillo</surname><given-names>VA</given-names></name><name><surname>Kuriyama</surname><given-names>R</given-names></name><name><surname>McIntosh</surname><given-names>JR</given-names></name></person-group><article-title>A plus-end-directed motor enzyme that moves antiparallel microtubules in vitro localizes to the interzone of mitotic spindles</article-title><source>Nature</source><year>1992</year><volume>359</volume><fpage>543</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1038/359543a0</pub-id><?supplied-pmid 1406973?><pub-id pub-id-type="pmid">1406973</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T-F</given-names></name><name><surname>Zeng</surname><given-names>H-J</given-names></name><name><surname>Shan</surname><given-names>Z</given-names></name><name><surname>Ye</surname><given-names>R-Y</given-names></name><name><surname>Cheang</surname><given-names>T-Y</given-names></name><name><surname>Zhang</surname><given-names>Y-J</given-names></name><etal/></person-group><article-title>Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer</article-title><source>Cancer Cell Int</source><year>2020</year><volume>20</volume><fpage>123</fpage><pub-id pub-id-type="doi">10.1186/s12935-020-01191-1</pub-id><?supplied-pmid 32322170?><pub-id pub-id-type="pmid">32322170</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>C-T</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S-N</given-names></name><name><surname>Guo</surname><given-names>X-F</given-names></name><name><surname>Zhou</surname><given-names>Y-Z</given-names></name></person-group><article-title>KIF23 enhances cell proliferation in pancreatic ductal adenocarcinoma and is a potent therapeutic target</article-title><source>Ann Transl Med</source><year>2020</year><volume>8</volume><fpage>1394</fpage><pub-id pub-id-type="doi">10.21037/atm-20-1970</pub-id><?supplied-pmid 33313139?><pub-id pub-id-type="pmid">33313139</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Wada</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>H-P</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Ujiie</surname><given-names>H</given-names></name><etal/></person-group><article-title>Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients</article-title><source>Lung Cancer (Amsterdam, Netherlands)</source><year>2016</year><volume>92</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2015.11.018</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name></person-group><article-title>Knockdown of lncRNA PVT1 inhibits prostate cancer progression in vitro and in vivo by the suppression of KIF23 through stimulating miR-15a-5p</article-title><source>Cancer Cell Int</source><year>2020</year><volume>20</volume><fpage>283</fpage><pub-id pub-id-type="doi">10.1186/s12935-020-01363-z</pub-id><?supplied-pmid 32624708?><pub-id pub-id-type="pmid">32624708</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Gan</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Shu</surname><given-names>G</given-names></name><etal/></person-group><article-title>Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23</article-title><source>Cell Cycle (Georgetown, Tex)</source><year>2019</year><volume>18</volume><fpage>1601</fpage><lpage>1618</lpage><pub-id pub-id-type="doi">10.1080/15384101.2019.1624112</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Gou</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>O</given-names></name><etal/></person-group><article-title>Identification of KIF23 as a prognostic signature for ovarian cancer based on large-scale sampling and clinical validation</article-title><source>Am J Transl Res</source><year>2020</year><volume>12</volume><fpage>4955</fpage><lpage>4976</lpage><?supplied-pmid 33042400?><pub-id pub-id-type="pmid">33042400</pub-id></element-citation></ref></ref-list></back></article>